A 13-week, multicenter, randomized controlled trial found that automated insulin delivery significantly reduced glycated hemoglobin levels in adults with insulin-treated type 2 diabetes compared to continuous glucose monitoring alone.
The study enrolled 319 patients across 21 centers in the U.S. and Canada. Findings showed that automated insulin delivery (AID) resulted in a reduced mean glycated hemoglobin (HbA1c) level, increased time in the target glucose range, and decreased mean glucose levels compared to the control group. Lead study author Yogish C. Kudva, MD, and colleagues noted that AID remained in automated mode for a median of 93% of the time, and adverse events were reported in a small percentage of AID users. The study supports AID as an effective intervention for insulin-treated type 2 diabetes and suggests the need for further studies to evaluate long-term outcomes.
